Keywords
How to Cite
Abstract
In recent years, interest in the problem of hyperuricemia and related diseases has increased. A special place is occupied by asymptomatic hyperuricemia. The article discusses the pathophysiological mechanisms of the influence of asymptomatic hyperuricemia on the development of cardiovascular diseases, in particular, proatherogenic processes, subclinical
inflammation, endothelial dysfunction, oxidative stress, plaque formation, and vascular calcification. Non-medicinal methods of correction are considered, which are primarily related to lifestyle, namely nutrition, physical activity, etc. The effect of pharmacotherapy of hyperuricemia, namely the role of xanthine oxidase inhibitors: allopurinol and febuxostat, in reducing
cardiovascular risk was analyzed. A consensus on the management of patients with hyperuricemia and high cardiovascular risk is presented.
References
2. Chen-Xu M, Yokose C, Rai SK et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019;71(6):991-999. DOI: 10.1002/art.40807.
3. Liu B, Wang T, Zhao HN et al. The prevalence of hyperuricemia in China: a meta-analysis. BMC Public Health. 2011;11:832. DOI: 10.1186/1471-2458-11-832.
4. Kim SY, Guevara JP, Kim KM et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62(2):170-180. DOI: 10.1002/acr.20065.
5. Stack AG, Hanley A, Casserly LF et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM. 2013;106(7):647-658. DOI: 10.1093/qjmed/hct083.
6. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82(3):421-426. DOI: 10.1016/0002-9343 (87) 90441-4.
7. Antelo-Pais P, Prieto-Díaz MÁ, Micó-Pérez RM et al. Prevalence of hyperuricemia and its association with cardiovascular risk factors and subclinical target organ damage. J Clin Med. 2022; 12(1):50. DOI: 10.3390/jcm12010050.
8. Perez-Ruiz F, Becker MA. Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015;31(Suppl 2):9-14. DOI: 10.1185/03007995.2015.1087980.
9. Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183-1190. DOI: 10.1161/01.HYP.0000069700.62727.C5.
10. Sánchez-Lozada LG, Tapia E, Avila-Casado C et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283(5):F1105-F1110. DOI: 10.1152/ajprenal.00170.2002.
11. Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperucemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol. 2000;49:511.
12. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and wh ere do they leave us? Am J Med. 2005;118(8):816-826. DOI: 10.1016/j.amjmed.2005.03.043.
13. Khanna P, Johnson RJ, Marder B et al. Systemic Urate Deposition: An Unrecognized Complication of Gout? J Clin Med. 2020;9(10):3204. DOI: 10.3390/jcm9103204.
14. Wang J, Qin T, Chen J et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9(12):e114259. DOI: 10.1371/journal.pone.0114259.
15. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102-110. DOI: 10.1002/acr.20344.